News & Events

Upcoming Events

There are currently no events to display.

Past Events

News Releases

Date Title and Summary
Toggle Summary Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
—74% (14/19) ORR and 68% (13/19) CR rate at 3 months and 50% (7/14) CR at 6 months in core group at dose level 2— —Across doses, 80% (16/20) of core group patients in CR at month 3 remain in response at month 6; 92% (11/12) of core group patients in response at 6 months remain in response as of
Toggle Summary Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL
— Patient factors may impact safety and efficacy outcomes— —JCAR017 cells infiltrated tumors, more infiltration trended with better response— —At disease progression, tumors tended to express CD19 and lack CAR T cells— SEATTLE --(BUSINESS WIRE)--Dec. 9, 2017-- Juno Therapeutics ,
Toggle Summary Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition
SEATTLE --(BUSINESS WIRE)--Dec. 6, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced three license agreements to advance its program in multiple myeloma using gamma secretase
Toggle Summary Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO
Experienced and accomplished executive additions with proven track records in scaling manufacturing, process development, and CMC portfolio management SEATTLE --(BUSINESS WIRE)--Nov. 27, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular
Toggle Summary Juno Therapeutics to Present at November 2017 Investor Conferences
SEATTLE --(BUSINESS WIRE)--Nov. 6, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in November. The presentations will feature a business overview and update by Steve Harr , Juno’s Chief Financial Officer and Head of
Toggle Summary Juno Therapeutics Reports Third Quarter 2017 Financial Results
- TRANSCEND pivotal trial ongoing using dose level 2 - - Promising data with JCAR017 in DLBCL at dose level 2: 80% (12/15) ORR and 73% (11/15) CR rate at 3 months in core group - - 1% (1/69) severe CRS and 14% (10/69) severe NT rates in full group: safety profile appears similar across doses as
Toggle Summary Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH
- 15 abstracts to be presented at upcoming ASH Conference - - Promising data with JCAR017 in DLBCL at dose level 2: 80% (12/15) ORR and 73% (11/15) CR rate at 3 months in core group - - Additional presentations on JCAR017 outpatient administration, JCAR017 translational insights, and multiple
Toggle Summary Juno Therapeutics to Report Third Quarter 2017 Financial Results on Wednesday, November 1
SEATTLE --(BUSINESS WIRE)--Oct. 25, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the third quarter 2017 on Wednesday, November 1, 2017 , after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and
Toggle Summary Juno Therapeutics Closes Follow-on Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SEATTLE --(BUSINESS WIRE)--Sep. 26, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the closing of its follow-on public offering of 7,015,000 shares of its common stock at a price
Toggle Summary Juno Therapeutics Prices $250 Million Follow-on Offering
SEATTLE --(BUSINESS WIRE)--Sep. 21, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the pricing of its follow-on public offering of 6,100,000 shares of its common stock at a price